Table 1. FDA-approved ICIs, their immune targets, and their common indications.

CTLA-4: cytotoxic T-lymphocyte associated antigen; PD-1: programmed cell death protein-1; PDL-1: programmed cell death protein ligand-1; FDA: Food and Drug Administration; ICIs: immune checkpoint inhibitors

ICI	Immune Target	Year Approved	Common Indications
Ipilimumab	CTLA-4	2011	Melanoma
Pembrolizumab	PD-1	2014	Non-small-cell lung cancer, melanoma
Nivolumab	PD-1	2014	Non-small-cell lung cancer, hepatocellular carcinoma, melanoma
Atezolizumab	PDL-1	2016	Non-small-cell lung cancer, urothelial carcinoma
Avelumab	PDL-1	2017	Merkel-cell carcinoma, urothelial carcinoma
Durvalumab	PDL-1	2017	Urothelial carcinoma
Cemiplimab	PD-1	2018	Metastatic cutaneous squamous cell carcinoma